190 related articles for article (PubMed ID: 23042259)
1. Pharmacogenetic determinant of the drug interaction between tacrolimus and omeprazole.
Zhao W; Fakhoury M; Maisin A; Baudouin V; Storme T; Deschênes G; Jacqz-Aigrain E
Ther Drug Monit; 2012 Dec; 34(6):739-41. PubMed ID: 23042259
[TBL] [Abstract][Full Text] [Related]
2. Pharmacokinetic interaction between tacrolimus and amlodipine in a renal transplant child.
Zhao W; Baudouin V; Fakhoury M; Storme T; Deschênes G; Jacqz-Aigrain E
Transplantation; 2012 Apr; 93(7):e29-30. PubMed ID: 22450597
[No Abstract] [Full Text] [Related]
3. Increased hospital stay and allograft dysfunction in renal transplant recipients with Cyp2c19 AA variant in SNP rs4244285.
Bosó V; Herrero MJ; Bea S; Galiana M; Marrero P; Marqués MR; Hernández J; Sánchez-Plumed J; Poveda JL; Aliño SF
Drug Metab Dispos; 2013 Feb; 41(2):480-7. PubMed ID: 23175667
[TBL] [Abstract][Full Text] [Related]
4. Tacrolimus concentrations in relation to CYP3A and ABCB1 polymorphisms among solid organ transplant recipients in Korea.
Jun KR; Lee W; Jang MS; Chun S; Song GW; Park KT; Lee SG; Han DJ; Kang C; Cho DY; Kim JQ; Min WK
Transplantation; 2009 Apr; 87(8):1225-31. PubMed ID: 19384171
[TBL] [Abstract][Full Text] [Related]
5. Frequencies and roles of CYP3A5, CYP3A4 and ABCB1 single nucleotide polymorphisms in Italian teenagers after kidney transplantation.
Turolo S; Tirelli AS; Ferraresso M; Ghio L; Belingheri M; Groppali E; Torresani E; Edefonti A
Pharmacol Rep; 2010; 62(6):1159-69. PubMed ID: 21273673
[TBL] [Abstract][Full Text] [Related]
6. Pharmacogenetic considerations for optimizing tacrolimus dosing in liver and kidney transplant patients.
Provenzani A; Santeusanio A; Mathis E; Notarbartolo M; Labbozzetta M; Poma P; Provenzani A; Polidori C; Vizzini G; Polidori P; D'Alessandro N
World J Gastroenterol; 2013 Dec; 19(48):9156-73. PubMed ID: 24409044
[TBL] [Abstract][Full Text] [Related]
7. Clinical and genetic factors affecting tacrolimus trough levels and drug-related outcomes in Korean kidney transplant recipients.
Kim IW; Moon YJ; Ji E; Kim KI; Han N; Kim SJ; Shin WG; Ha J; Yoon JH; Lee HS; Oh JM
Eur J Clin Pharmacol; 2012 May; 68(5):657-69. PubMed ID: 22183771
[TBL] [Abstract][Full Text] [Related]
8. Population pharmacokinetics and pharmacogenetics of tacrolimus in de novo pediatric kidney transplant recipients.
Zhao W; Elie V; Roussey G; Brochard K; Niaudet P; Leroy V; Loirat C; Cochat P; Cloarec S; André JL; Garaix F; Bensman A; Fakhoury M; Jacqz-Aigrain E
Clin Pharmacol Ther; 2009 Dec; 86(6):609-18. PubMed ID: 19865079
[TBL] [Abstract][Full Text] [Related]
9. Distinct effects of omeprazole and rabeprazole on the tacrolimus blood concentration in a kidney transplant recipient.
Takahashi K; Yano I; Fukuhara Y; Katsura T; Takahashi T; Ito N; Yamamoto S; Ogawa O; Inui K
Drug Metab Pharmacokinet; 2007 Dec; 22(6):441-4. PubMed ID: 18159131
[TBL] [Abstract][Full Text] [Related]
10. CYP3A5 and CYP3A4 but not MDR1 single-nucleotide polymorphisms determine long-term tacrolimus disposition and drug-related nephrotoxicity in renal recipients.
Kuypers DR; de Jonge H; Naesens M; Lerut E; Verbeke K; Vanrenterghem Y
Clin Pharmacol Ther; 2007 Dec; 82(6):711-25. PubMed ID: 17495880
[TBL] [Abstract][Full Text] [Related]
11. Influence of ABCB1 C3435T polymorphism on the pharmacokinetics of lansoprazole and gastroesophageal symptoms in Japanese renal transplant recipients classified as CYP2C19 extensive metabolizers and treated with tacrolimus.
Miura M; Satoh S; Tada H; Saito M; Kagaya H; Inoue K; Sagae Y; Kanno S; Ishikawa M; Habuchi T; Suzuki T
Int J Clin Pharmacol Ther; 2006 Dec; 44(12):605-13. PubMed ID: 17190370
[TBL] [Abstract][Full Text] [Related]
12. Influence of CYP3A4, CYP3A5 and MDR-1 polymorphisms on tacrolimus pharmacokinetics and early renal dysfunction in liver transplant recipients.
Shi Y; Li Y; Tang J; Zhang J; Zou Y; Cai B; Wang L
Gene; 2013 Jan; 512(2):226-31. PubMed ID: 23107770
[TBL] [Abstract][Full Text] [Related]
13. CYP3A and ABCB1 genetic polymorphisms on the pharmacokinetics and pharmacodynamics of tacrolimus and its metabolites (M-I and M-III).
Yoon SH; Cho JH; Kwon O; Choi JY; Park SH; Kim YL; Yoon YR; Won DI; Kim CD
Transplantation; 2013 Mar; 95(6):828-34. PubMed ID: 23364483
[TBL] [Abstract][Full Text] [Related]
14. Lansoprazole-tacrolimus interaction in Japanese transplant recipient with CYP2C19 polymorphism.
Takahashi K; Motohashi H; Yonezawa A; Okuda M; Ito N; Yamamoto S; Ogawa O; Inui K
Ann Pharmacother; 2004 May; 38(5):791-4. PubMed ID: 15010519
[TBL] [Abstract][Full Text] [Related]
15. Pharmacogenetic determinants for interindividual difference of tacrolimus pharmacokinetics 1 year after renal transplantation.
Miura M; Niioka T; Kagaya H; Saito M; Hayakari M; Habuchi T; Satoh S
J Clin Pharm Ther; 2011 Apr; 36(2):208-16. PubMed ID: 21366650
[TBL] [Abstract][Full Text] [Related]
16. CYP3A7, CYP3A5, CYP3A4, and ABCB1 genetic polymorphisms, cyclosporine concentration, and dose requirement in transplant recipients.
Crettol S; Venetz JP; Fontana M; Aubert JD; Pascual M; Eap CB
Ther Drug Monit; 2008 Dec; 30(6):689-99. PubMed ID: 18978522
[TBL] [Abstract][Full Text] [Related]
17. The interactions of age, sex, body mass index, genetics, and steroid weight-based doses on tacrolimus dosing requirement after adult kidney transplantation.
Stratta P; Quaglia M; Cena T; Antoniotti R; Fenoglio R; Menegotto A; Ferrante D; Genazzani A; Terrazzino S; Magnani C
Eur J Clin Pharmacol; 2012 May; 68(5):671-80. PubMed ID: 22101623
[TBL] [Abstract][Full Text] [Related]
18. Effect of lansoprazole and rabeprazole on tacrolimus pharmacokinetics in healthy volunteers with CYP2C19 mutations.
Itagaki F; Homma M; Yuzawa K; Nishimura M; Naito S; Ueda N; Ohkohchi N; Kohda Y
J Pharm Pharmacol; 2004 Aug; 56(8):1055-9. PubMed ID: 15285851
[TBL] [Abstract][Full Text] [Related]
19. Switching from intravenous to oral tacrolimus and voriconazole leads to a more pronounced drug-drug interaction.
Spriet I; Grootaert V; Meyfroidt G; Debaveye Y; Willems L
Eur J Clin Pharmacol; 2013 Mar; 69(3):737-8. PubMed ID: 22878691
[No Abstract] [Full Text] [Related]
20. Effect of CYP3A5, CYP3A4, and ABCB1 genotypes as determinants of tacrolimus dose and clinical outcomes after heart transplantation.
Díaz-Molina B; Tavira B; Lambert JL; Bernardo MJ; Alvarez V; Coto E
Transplant Proc; 2012 Nov; 44(9):2635-8. PubMed ID: 23146479
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
